This strategy report outlines five actionable priorities to improve bladder cancer care across health systems. It also focuses on patient education, care coordination, referral pathways, provider knowledge, and program measurement. The report addresses the challenges posed by high recurrence rates, complex patient populations, and evolving therapies, highlighting the need for standardized, guideline-concordant care. Published - April 2026

The Time Back campaign for cancer care honors oncologists, the emotional burdens they carry, and the work they do to help make more moments possible for people living with cancer. 

https://www.bms.com/healthcare-providers/time-back-campaign-honoring-oncologists-in-cancer-care.html

Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer

ASCENT-04 published in New England Journal of Medicine: 

https://www.nejm.org/doi/full/10.1056/NEJMoa2508959

Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer

ASCENT-03 published in New England Journal of Medicine: 

https://www.nejm.org/doi/full/10.1056/NEJMoa2511734

Pfizer and the American Cancer Society are teaming up through Change the Odds to help break barriers in cancer care disparities with a focus on: Cancer Screening, Patient Resources & support, and Clinical Trials. Learn more below.

This brochure from Regeneron provides helpful information on advanced CSCC and advanced BCC in patients of color.

Joint initiative to focus on expanding early detection and equitable access to care through lung cancer specific AI workflows on Microsoft’s suite of radiology solutions

Study marks the first positive Phase 3 study for mezigdomide and the second positive Phase 3 study for the Bristol Myers Squibb CELMoD program. 

A patient and caregiver website to learn more and find resources about each step of the CAR T cell therapy journey. Visit 

 or download the resource below to learn more.

The Inflation Reduction Act of 2022 included several provisions to reduce OOP costs for Medicare Part D medicines:¹-3

In 2026, $2,100 is the total maximum OOP cost patients will pay for their covered Part D drugs. This includes their annual deductible.

Patients have the option to spread their OOP costs out over the course of the year by opting in to the Medicare Prescription Payment Plan.

In addition to surgery, with the evolution of new treatment options, surgeons play a role in referral of patients to medical oncologists or the multidisciplinary team. Coordination with the medical oncologist and the entire care team can help facilitate the development of a treatment plan for patients. The resource will review some factors that may be relevant when considering neoadjuvant and adjuvant therapies.

Bone marrow biopsies play a critical role in diagnosing, staging, and monitoring treatment response in AML. In this expert-led educational video, Thomas LeBlanc, MD, MA, MHS, hematologist-oncologist, associate professor of medicine and population health sciences at Duke Cancer Institute, and Keri Halsema, MSN, NP, nurse practitioner and senior instructor in the Cell Therapy Center at University of Colorado, walk through essential best practices for performing and interpreting bone marrow biopsies in AML care. Topics include key diagnostic tests, biopsy techniques, outpatient procedural considerations, and strategies to improve provider confidence through training and simulation. The video also highlights the importance of patient education, interdisciplinary coordination, and timely lab processing to support optimal outcomes.

To view the full publication, please refer to San-Miguel, J, et al. N Engl J Med. 2023;389(4):335-347 or click the resource below to view the Plain Language Summary of Publication of this article.

MyHealthcareFinances is a freely available website to help patients and caregivers understand finances related to healthcare and steps that may lower costs. The site is a collaboration between Pfizer and Triage Cancer, joining people with a shared passion for improving healthcare-related financial literacy. Visit 

Pfizer is committed to supporting patients throughout their treatment journey. With Pfizer Oncology Together, patients prescribed a Pfizer Oncology medication can get help identifying financial assistance options and be connected to resources that may help with some of their day-to-day challenges.

Pfizer Oncology Together can help healthcare providers by:

Assisting with benefits verification, prior authorizations, appeals, billing and coding, and specialty pharmacy coordination

Connecting them and their office staff to a Pfizer Field Reimbursement Manager (FRD) who can help address specific access and reimbursement issues—in person or over the phone

Offering and assisting with online portals that provide registered users with access and financial assistance resources

Pfizer Oncology Together can help patients by:

Connecting them with financial assistance resources—regardless of their insurance coverage

Providing personalized support from a Pfizer Oncology FRM who can help identify resources and organizations that may provide additional assistance

 for more details, or contact your local FRM or AP&R Director to learn more.

This new publication explores real-world safety and efficacy in patients treated with a CD123 targeted therapy in newly diagnosed blastic plasmacytoid dendritic cell neoplasms.

Despite advances in the adjuvant treatment of early-stage estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer, there continues to be a risk of recurrence. The ELEGANT study is a Global, Multicenter, Randomized, Open-label Phase 3 Study with the primary goal to evaluate the efficacy and safety of elacestrant versus standard endocrine therapy in participants with node-positive ER+/HER2- early breast cancer with high risk of recurrence. The main purpose of this study is to compare the Invasive Breast Cancer-Free Survival (IBCFS) over a period of up to 5 years. 4220 participants will be included in this study around the world. Participants will have equal chance to be assigned to receive either of the treatment combinations.




Anemia is a hallmark of MDS, conferring heightened mortality risk and diminished quality of life. Please feel free to view & share this important resource.



Elacestrant significantly prolonged progression-free survival (PFS) with manageable safety versus standard-of-care (SOC) endocrine therapy (ET) in patients with estrogen receptor–positive (ER+), HER2− metastatic breast cancer and tumors harboring estrogen receptor 1 (ESR1) mutation following ET plus a cyclin-dependent kinase 4/6 inhibitor (ET+CDK4/6i).







Nearly 1 out of 2 people with ER+/HER2- metastatic breast cancer may develop an ESR1 mutation after progression on hormone therapy.

Learn more about this ESR1 mutation at 

 is a cancer that affects your blood and the soft tissue inside your bones, which is called bone marrow. It can also affect other parts of your body, such as your lymph nodes, spleen, central nervous system, and skin.

Learn more about this hematologic disease at 

To improve outcomes for patients with acute myeloid leukemia, especially those who do not receive a transplant, the Association of Cancer Care Centers (ACCC), with support from 

, has partnered with the HealthTree Foundation for Acute Myeloid Leukemia to develop a 

This new white paper demonstrates the time-burden on ER+, HER2- mBC patients and their loved ones when going to receive care and the potential difficulty of care when an IM injection is part of their treatment plan. It has been published by Ipsos and Living Beyond Breast Cancer, and is supported by 

This resource was created by Patient Resource and GO2 for Lung Cancer and produced with support from 

 to provide patients and their loved ones with comprehensive information to guide them throughout their journey with small cell lung cancer. A Spanish-speaking version is available via download.
Free copies of this resource can be obtained by ordering it by:

Educational Resources

EDUCATIONAL RESOURCES

KYSCO 2025 Inmunotherapy Meeting

5 strategies to close gaps in bladder cancer care. Reducing variations in treatment and promoting guideline-concordant bladder cancer care

Bristol Myers Squibb’s Time Back campaign honors the most precious gift oncologists provide in cancer care: time

View these recent articles in the New England Journal of Medicine from our member

Change the Odds: Uniting to Improve Cancer Outcomes™

Explore Two New Publications on Real-World-Evidence in ESR1-mutated Metastatic Breast Cancer

2026 Regeneron The Different Colors of Skin Cancer Brochure

Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer

Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma

Learn about CAR-T Cell Therapy in Earlier Lines of Treatment for Relapsed or Refractory Multiple Myeloma

Help patients explore everything CAR T Cell Therapy